[Enteral hyperoxalosis due to therapy with a somatostatin analog].
A 27-year-old woman with multiple bilobal liver metastases of a carcinoid tumour and carcinoid syndrome was treated with the somatostatin analogue Octreotide, 450-600 micrograms daily subcutaneously. This improved previous attacks of marked epigastric pain, while endocrine activity and tumour mass remained unchanged. Shortly after treatment had begun, soft fatty stools and oxaluria were noted. After six months severe renal colics were found to be due to non-opaque caliceal calculi, and a contracted non-functioning gallbladder was discovered. The calculi consisted of oxalate. The enteric hyperoxalosis, oxaluria and urolithiasis were presumably side effects of the Octreotide treatment.
Ranft
K
K
Innere Abteilung des Städtischen Krankenhauses Penzberg.
Eibl-Eibesfeldt
B
B
D000328:Adult; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D006959:Hyperoxaluria / Q000139:chemically induced*; D007669:Kidney Calculi / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy*; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use
D015282:Octreotide
Enterale Hyperoxalose bei Therapie mit Somatostatin-Analoga.